4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note released on Friday morning,Weiss Ratings reports.

A number of other research analysts also recently weighed in on the stock. Roth Capital lowered their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday, October 21st. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

4D Molecular Therapeutics Stock Up 13.4%

Shares of 4D Molecular Therapeutics stock opened at $11.34 on Friday. The company has a market cap of $529.58 million, a price-to-earnings ratio of -3.21 and a beta of 2.93. The company’s 50 day moving average is $8.00 and its 200 day moving average is $5.45. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. Sell-side analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently bought and sold shares of FDMT. BVF Inc. IL raised its holdings in 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company’s stock worth $14,733,000 after purchasing an additional 1,890,647 shares during the period. Federated Hermes Inc. raised its position in shares of 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock valued at $4,038,000 after purchasing an additional 1,246,419 shares during the period. Acadian Asset Management LLC raised its position in shares of 4D Molecular Therapeutics by 1,103.4% during the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock valued at $1,290,000 after purchasing an additional 367,317 shares during the period. Millennium Management LLC raised its position in shares of 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after purchasing an additional 213,264 shares during the period. Finally, Raymond James Financial Inc. raised its position in shares of 4D Molecular Therapeutics by 54.7% during the 2nd quarter. Raymond James Financial Inc. now owns 455,470 shares of the company’s stock valued at $1,690,000 after purchasing an additional 161,091 shares during the period. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.